Tenax Therapeutics Statistics
Share Statistics
Tenax Therapeutics has 3.41M shares outstanding. The number of shares has increased by -85.71% in one year.
| Shares Outstanding | 3.41M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 74.08% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.98M |
| Failed to Deliver (FTD) Shares | 4.20K |
| FTD / Avg. Volume | 6.5% |
Short Selling Information
The latest short interest is 105.76K, so 3.1% of the outstanding shares have been sold short.
| Short Interest | 105.76K |
| Short % of Shares Out | 3.1% |
| Short % of Float | 3.55% |
| Short Ratio (days to cover) | 1.46 |
Valuation Ratios
The PE ratio is -0.71 and the forward PE ratio is -0.96.
| PE Ratio | -0.71 |
| Forward PE | -0.96 |
| PS Ratio | 0 |
| Forward PS | 9.9 |
| PB Ratio | 0.67 |
| P/FCF Ratio | -0.92 |
| PEG Ratio | n/a |
Enterprise Valuation
Tenax Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 3.26, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.26 |
| Quick Ratio | 3.26 |
| Debt / Equity | 0.06 |
| Total Debt / Capitalization | 5.83 |
| Cash Flow / Debt | -11.79 |
| Interest Coverage | -343.55 |
Financial Efficiency
Return on equity (ROE) is -0.95% and return on capital (ROIC) is -95.75%.
| Return on Equity (ROE) | -0.95% |
| Return on Assets (ROA) | -0.66% |
| Return on Capital (ROIC) | -95.75% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.54M |
| Employee Count | 5 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -71.9% in the last 52 weeks. The beta is 2.15, so Tenax Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.15 |
| 52-Week Price Change | -71.9% |
| 50-Day Moving Average | 4.72 |
| 200-Day Moving Average | 3.91 |
| Relative Strength Index (RSI) | 62.31 |
| Average Volume (20 Days) | 64.61K |
Income Statement
In the last 12 months, Tenax Therapeutics had revenue of $0 and earned -$7.71M in profits. Earnings per share was $-31.09.
| Revenue | 0 |
| Gross Profit | -7.57K |
| Operating Income | -8.23M |
| Net Income | -7.71M |
| EBITDA | -8.23M |
| EBIT | - |
| Earnings Per Share (EPS) | -31.09 |
Balance Sheet
The company has $9.79M in cash and $500.90K in debt, giving a net cash position of $9.29M.
| Cash & Cash Equivalents | 9.79M |
| Total Debt | 500.90K |
| Net Cash | 9.29M |
| Retained Earnings | -297.25M |
| Total Assets | 99.78M |
| Working Capital | 97.22M |
Cash Flow
In the last 12 months, operating cash flow was -$5.90M and capital expenditures $2.84K, giving a free cash flow of -$5.90M.
| Operating Cash Flow | -5.90M |
| Capital Expenditures | 2.84K |
| Free Cash Flow | -5.90M |
| FCF Per Share | -23.8 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
TENX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -533.28% |
| FCF Yield | -29.68% |
Analyst Forecast
The average price target for TENX is $16, which is 174.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $16 |
| Price Target Difference | 174.4% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Jan 3, 2024. It was a backward split with a ratio of 1:80.
| Last Split Date | Jan 3, 2024 |
| Split Type | backward |
| Split Ratio | 1:80 |
Scores
| Altman Z-Score | 1.34 |
| Piotroski F-Score | 2 |